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Abstract
The present commentary provides a brief overview of the evolving
literature on glycemic management in critically ill patients. Recent
interventional studies have been plagued by high rates of severe
hypoglycemia among patients, particularly those with sepsis. The
investigation by Waeschle and colleagues adds to our knowledge
about the relationship between the severity of sepsis and glycemic
dysregulation. The severity of sepsis is shown to correlate with the
risk of sustaining hyperglycemia as well as critical hypoglycemia.
The previous issue of Critical Care featured work by Waeschle
and coinvestigators describing the interaction between two
topics of great interest to intensivists: sepsis and glycemic
management [1]. The publication of the first Leuven trial
ushered into intensive care a new treatment paradigm: monitor-
ing and treating even modest degrees of hyperglycemia in
critically ill patients improved outcomes [2]. We have learned a
great deal in the 7 years since this landmark study.
Van den Berghe and colleagues treated a narrow population
of surgical intensive care unit (ICU) patients: all were mecha-
nically ventilated, and 63% had undergone cardiovascular
surgery. The rate of severe hypoglycemia (SH) (blood glucose
<40 mg/dl) was low, perhaps in part due to the participation
of study physicians not directly involved in patient care who
actively monitored the glycemic management protocol [2].
Confirmation of the benefit of intensive glycemic monitoring
and treatment followed 3 years later in the Stamford trial, a
before and after intervention completed in a mixed medical–
surgical ICU setting [3]. Tellingly, there was no difference in
the rate of SH between the two groups in that study.
Subsequent trials met a somewhat different fate. The second
Leuven trial, performed in a medical ICU, demonstrated
decreased mortality in the predefined population of patients
treated for more than 3 days, but not in the entire treated
population [4]. The number of patients sustaining SH was
strikingly higher in the treated group compared with that seen
in the control arm (18.7% versus 3.1%, respectively). Two
studies initially reported in 2006 – the Efficacy of Volume
Substitution and Insulin Therapy in Severe Sepsis (VISEP)
trial, a multicenter investigation limited to patients with severe
sepsis; and the Glucontrol trial, a multicenter study in a mixed
group of medical and surgical ICUs – were terminated
prematurely by their respective safety boards, in part due to
excessive rates of SH in the treatment arms [5,6].
More recently, two studies in large observational cohorts
have identified sepsis as an important risk factor for the
development of SH [7,8]. One group found that a single
episode of SH was associated with a significant increased
risk of mortality, using multivariable regression analysis as
well as a case–control methodology [8].
Two important conclusions emerge from this body of
research. It matters how glycemic control is implemented: SH
is deleterious. Moreover, this issue is especially relevant in
patients with sepsis, who appear to be at heightened risk for
the development of SH.
It is in this context that the study by Waeschle and coworkers
makes a valuable contribution to the literature on glycemic
management of critically ill patients [1]. The investigators
analyzed various indices of glycemic control in a cohort of
191 patients, treated with an insulin protocol targeting 80 to
140 mg/dl, who were admitted with sepsis or who developed
sepsis during admission to a predominantly surgical ICU.
Patients were stratified by the severity of sepsis: sepsis
patients (n = 47), severe sepsis patients (n = 83) and septic
shock patients (n = 61).
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The percentage of patients with at least one episode of SH
increased as the severity of the category of sepsis increased:
2.1%, 6.0% and 11.5% for patients with sepsis, severe
sepsis and septic shock, respectively. Unfortunately the
authors do not indicate the relative percentage of insulin-
related or spontaneously occurring critical hypoglycemia. In
the study by Krinsley and Grover, 27.5% of the patients with
SH had not received any insulin within 12 hours of the
occurrence of hypoglycemia [8].
The severity of sepsis also impacted the occurrence of
hyperglycemia; the percentage of patients with blood glucose
>179 mg/dl was 55.3%, 73.5% and 88.5% for patients with
sepsis, severe sepsis and septic shock, respectively.
Moreover, both the duration and intensity of insulin therapy
was positively associated with the severity of sepsis. The
median duration of continuous insulin therapy was
83.4 hours, 101.1 hours and 217.6 hours, and the median
insulin dose per day applied over the entire ICU stay was
33.2 units, 36.3 units and 45.0 units for patients with sepsis,
severe sepsis and septic shock, respectively. These data
reflect the increased degree of metabolic derangement
associated with full-blown septic shock.
Interestingly, the study by Waeschle and colleagues also
evaluated glycemic variability, defined as the standard
deviation (SD) of the mean glucose level occurring during the
sepsis episodes. Multivariable regression analysis demon-
strated that the SD was positively associated with the
development of SH. Moreover, increased glycemic variability
was strongly associated with mortality in this cohort: 24.0%
versus 2.5%, comparing patients with SD >20 mg/dl or
<20 mg/dl. Indeed, every patient with severe sepsis and
septic shock who died had a SD >20 mg/dl [1]. These
results corroborate recent investigations in medical–surgical
ICU populations [9,10], in a single-center surgical ICU cohort
[11] and in a cohort of patients specifically with sepsis [12]
that demonstrated the significant effect of glycemic variability
on outcome of critically ill patients.
How do we integrate the findings of the current study into
clinical practice? Sepsis is clearly associated with distur-
bances in glucose regulation, and the occurrence of hypo-
glycemia (both spontaneous and treatment-related) and
hyperglycemia increase along the continuum from sepsis
through severe sepsis to septic shock. Glycemic variability
may also be positively associated with the severity of sepsis,
although the current study was underpowered to demon-
strate this unequivocally. The failure of the VISEP
investigators to complete enrollment for their trial of intensive
insulin therapy in a population of septic shock, due to the very
high rate of SH, is quite understandable in this context.
Safe, effective glycemic control may be a useful paradigm to
replace tight glycemic control, especially in a population –
such as the patients described in the current investigation –
that is inherently susceptible to major disturbances in
glycemic regulation [13]. The principles of this emerging
model include the choice of a glycemic target that does not
yield excessive rates of severe hypoglycemia and the optimal
implementation of protocols, assisted by the possible use of
data outcome tools, electronic algorithms and, eventually,
continuous or near-continuous glucose monitors. Successful
application of this approach offers the best opportunity for
clinicians to maintain blood glucose levels in the chosen
range, to minimize glycemic variability and to yield the best
outcomes for our patients.
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